Clinaptis Advisors Publishes Phase 3 CSU Catalyst Preview on Celldex Therapeutics' Barzolvolimab

NEW DELHI - Aug. 15, 2026 - PRLog -- Clinaptis Advisors today published a new institutional research report on Celldex Therapeutics (CLDX) and barzolvolimab ahead of Phase 3 EMBARQ-CSU topline results in chronic spontaneous urticaria (CSU), expected in September/October 2026.

The report examines barzolvolimab's Phase 2 efficacy. safety, Phase 3 statistical hurdles, outcomes in omalizumab-refractory patients, complete-response benchmarks against remibrutinib and Xolair, and valuation across a joint two-trial framework.

CSU is a chronic inflammatory skin disease causing recurrent hives and/or swelling, often without an identifiable trigger, with substantial quality-of-life burden.

"The primary endpoint is increasingly the wrong question," said Bikram K. Singh, MBBS, Founder of Clinaptis Advisors. "The statistical efficacy hurdle looks relatively easy to clear versus Phase 2. But a positive readout may not be enough. The key question is whether barzolvolimab preserves complete-response differentiation — particularly in omalizumab-refractory patients — without meaningful KIT-related safety friction."

Among the report's principal findings:

• Estimates a Phase 3 hurdle of approximately 1.8 UAS7 points, versus a modeled 9–10 point treatment effect.
• Forecasts complete response of ~43%/32% for the two barzolvolimab regimens, versus ~28–31% for remibrutinib and 34–44% for Xolair at Week 12.
• Models both EMBARQ trials jointly, including discordant trials, refractory-subgroup failure and safety-limited outcomes.
• Estimates Base SOTP at $39.28/share and probability-weighted catalyst value at $38.72/share, versus a $41.70 reference price.
• Finds differentiated/BIC scenarios support ~49–70% upside, versus ~34–39% downside in discordant or partial-failure outcomes.
• Examines KIT-related neutropenia and pigmentation changes as potential commercial liabilities.

"Barzolvolimab can work and the stock can still disappoint," Singh added. "A clean positive readout could push CLDX above $50, but today's valuation already discounts economics close to our Base case. The more compelling long case requires clear complete-response differentiation. That makes EMBARQ a differentiation test, not simply a p-value event."

CLDX already prices CSU near our Base case, leaving us cautious on an outright pre-catalyst long and favoring a better entry or defined-risk structure.

The full report is available on the Clinaptis Research website:
https://www.clinaptisresearch.com/p/celldex-a-positive-cs...

About Clinaptis Advisors

Clinaptis Advisors is an independent biotechnology research and advisory platform translating clinical development, regulatory science and commercial strategy into actionable investment research. Its work emphasizes primary-source analysis, evidence-based valuation and catalyst-driven due diligence.

Contact
Bikram K. Singh, MBBS
Clinaptis Advisors | Clinaptis Research
Founder & Principal Analyst
bikram@clinaptisresearch.com